Physician profile
Joseph S Bryan
NPI 1881686558
$87,889.52
in general payments reported to CMS, 2019-2025
21 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,744 · 2020: $3,482 · 2021: $15K · 2022: $10K · 2023: $1,383 · 2024: $52K · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $50K · Food and Beverage: $3,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $50,000.00 |
| Food and Beverage | $3,449.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $82,825.07 | 2019-2024 | |
| Alimera Sciences, INC. | $1,559.86 | 2023-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $665.48 | 2022-2025 | Stellaris, Stellaris, Xipere |
| Genentech USA, INC. | $569.95 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $551.80 | 2019-2025 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $302.10 | 2019 | |
| Abbvie INC. | $264.49 | 2019-2025 | Ozurdex |
| Allergan, INC. | $174.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $141.94 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.78 | 2019 | |
| Ani Pharmaceuticals, INC. | $132.25 | 2025 | Yutiq |
| Alcon Vision LLC | $112.76 | 2019 | |
| Eyepoint US, INC. | $108.95 | 2020 | |
| Astellas Pharma US INC | $89.49 | 2024-2025 | Izervay |
| Mallinckrodt Enterprises LLC | $55.28 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $48.16 | 2023 | |
| Genentech, INC. | $47.20 | 2023 | Susvimo, Vabysmo |
| Regeneron Pharmaceuticals, INC. | $46.83 | 2024 | Eylea Hd |
| Harrow Eye, LLC | $21.84 | 2024 | Iheezo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $15.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$442,937.57 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.